Logo

American Heart Association

  16
  0


Final ID: MP192

Diagnostic Performance of the ATTR-CM Mayo Score in Black and Hispanic individuals: Findings from SCAN-MP

Abstract Body (Do not enter title and authors here): Background: The Mayo transthyretin amyloidosis cardiomyopathy (ATTR-CM) score was developed to screen for ATTR-CM and guide referral for 99mTc-pyrophosphate imaging. However, its performance in Black or Hispanic individuals remains uncertain.
Hypothesis: We hypothesize that the Mayo ATTR-CM score will demonstrate similar diagnostic performance in a cohort of self-identified Hispanic and Black patients.
Aim: To evaluate the ATTR-CM Mayo score accuracy in the SCAN-MP study (Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations)
Methods: SCAN-MP was a prospective, multicenter study designed to evaluate the prevalence and diagnostic strategies for ATTR-CM in at-risk minority populations. ATTR-CM was identified by radionuclide cardiac imaging using single-photon emission computed tomography(SPECT) or endomyocardial biopsy. The Mayo ATTR-CM score was calculated as published. Logistic regression analysis was used to evaluate the performance of the ATTR-CM score to identify patients with ATTR-CM. Model calibration goodness-of-fit was determined by Hosmer-Lemeshow. ROC curves were constructed and sensitivity, specificity, positive and negative predictive values (PPV, NPV) were calculated.
Results: Our cohort included 646 individuals screened for ATTR-CM, of whom 43 (6.7%) were diagnosed with ATTR-CM, with a mean age 80 ± 8 years, 17 (40%) female, 19 (44%) with the V142I variant. Among the 603 (93%) without clinical ATTR-CM, the mean age was 73 ± 9 years, 310 (51%) were female, and 17 (2.8%) carried V142I. An ATTR-CM score of ≥6 had a AUC of 0.79 (95% CI: 0.72-0.86) to discriminate ATTR-CM, with a sensitivity of 64%, specificity of 79%, PPV of 17%, and a NPV of 0.97. The model demonstrated good calibration (χ2 = 2.97, p = 0.70).
Conclusion: The ATTR-CM score is a simple and effective clinical tool to screen for ATTR-CM in self-identified Hispanic and Black patients with heart failure. A score of <6 points confers a high NPV value, thereby useful to exclude ATTR-CM
  • Barrera, Nelson  ( Columbia University Medical Center , New York , New York , United States )
  • Ruberg, Frederick  ( Boston University Medical Center , Boston , Massachusetts , United States )
  • Miller, Edward  ( Yale University School of Medicine , Guilford , Connecticut , United States )
  • Maurer, Mathew  ( Columbia University Medical Center , New York , New York , United States )
  • Teruya, Sergio  ( Columbia University Medical Center , New York , New York , United States )
  • Helmke, Stephen  ( Columbia University Medical Center , New York , New York , United States )
  • Alreshq, Rabah  ( Boston University Medical Center , Boston , Massachusetts , United States )
  • Fine, Denise  ( Boston University Medical Center , Boston , Massachusetts , United States )
  • Ullah, Ikram  ( Boston University Medical Center , Boston , Massachusetts , United States )
  • Raiszadeh, Farbod  ( Harlem Hospital Center , New York , New York , United States )
  • Ionescu, Natalia  ( Harlem Hospital Center , New York , New York , United States )
  • Gallegos, Cesia  ( Yale University School of Medicine , Guilford , Connecticut , United States )
  • Author Disclosures:
    Nelson Barrera: DO NOT have relevant financial relationships | Frederick Ruberg: DO have relevant financial relationships ; Consultant:eMyosound:Active (exists now) ; Researcher:Anumana:Active (exists now) ; Researcher:BridgeBio:Active (exists now) ; Researcher:TriNetX:Active (exists now) ; Consultant:Attralus:Active (exists now) | Edward Miller: No Answer | Mathew Maurer: DO have relevant financial relationships ; Advisor:Pfizer:Active (exists now) ; Advisor:Intellia:Active (exists now) ; Advisor:BrigdeBio:Active (exists now) ; Advisor:AstraZeneca:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Alnylam:Active (exists now) | Sergio Teruya: DO NOT have relevant financial relationships | Stephen Helmke: No Answer | Rabah Alreshq : DO NOT have relevant financial relationships | Denise Fine: DO NOT have relevant financial relationships | Ikram Ullah: No Answer | Farbod Raiszadeh: No Answer | Natalia Ionescu: No Answer | Cesia Gallegos: DO have relevant financial relationships ; Advisor:Pfizer:Past (completed) ; Advisor:Astra Zeneca:Past (completed) ; Advisor:Alnylam:Past (completed) ; Advisor:Bridge Bio:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Heart Failure and Cardiomyopathies: Management

Saturday, 11/08/2025 , 01:45PM - 03:00PM

Moderated Digital Poster Session

More abstracts on this topic:
More abstracts from these authors:
Fully Automated vs. Human Echocardiogram Interpretation in Transthyretin Amyloid Cardiomyopathy: The SCAN-MP Study

Mcmenamin Katie, Lang Roberto, Maurer Mathew, Ruberg Frederick, Teruya Sergio, Slivnick Jeremy, Alreshq Rabah, Ullah Ikram, Fine Denise, Helmke Stephen, Gallegos Cesia, Miller Edward

Machine learning of echocardiographic left ventricular myocardial radiomics for identification of transthyretin amyloid cardiomyopathy

Elzieny Ali, Lang Roberto, Maurer Mathew, Li Baojun, Ruberg Frederick, Alreshq Rabah, Ullah Ikram, Fine Denise, Teruya Sergio, Helmke Steve, Gallegos Cesia, Miller Edward, Slivnick Jeremy

You have to be authorized to contact abstract author. Please, Login
Not Available